N-terminal pro-B-type natriuretic peptide in patients with growth hormone disturbances

Clinical Endocrinology

Volumn 66, Issue 5, 2007, Pages 619-625

  Andreassen, Mikkel ^a,b   Faber, Jens ^a   Vestergaard, Henrik ^a   Kistorp, Caroline ^a   Kristensen, Lars Østergaard ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b KAS Herlev   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOPEPTIN; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GROWTH HORMONE DEFICIENCY; HUMAN; HYPERTENSION; MALE; MEASUREMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT DURATION;

ACROMEGALY; ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS, HORMONAL; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; OCTREOTIDE; PEPTIDE FRAGMENTS; PEPTIDES, CYCLIC; PROTEIN PRECURSORS; RETROSPECTIVE STUDIES; SOMATOSTATIN; STATISTICS, NONPARAMETRIC;

EID: 34247876009     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2007.02782.x     Document Type: Article

References (47)

1. Frystyk, J., Ledet, T., Moller, N., Flyvbjerg, A. Orskov, H. (2002) Cardiovascular disease and insulin-like growth factor I. Circulation, 106, 893 895.
2. Colao, A., Marzullo, P., Di, S.C. Lombardi, G. (2001) Growth hormone and the heart. Clinical Endocrinology, 54, 137 154.
3. Moller, J. (2003) Effects of growth hormone on fluid homeostasis. Clinical and experimental aspects. Growth Hormone and IGF Research, 13, 55 74.
4. Clayton, R.N. (2003) Cardiovascular function in acromegaly. Endocrine Review, 24, 272 277.
5. Rajasoorya, C., Holdaway, I.M., Wrightson, P., Scott, D.J. Ibbertson, H.K. (1994) Determinants of clinical outcome and survival in acromegaly. Clinical Endocrinology, 41, 95 102.
6. Lopez-Velasco, R., Escobar-Morreale, H.F., Vega, B., Villa, E., Sancho, J.M., Moya-Mur, J.L. Garcia-Robles, R. (1997) Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension? Journal of Clinical Endocrinology and Metabolism, 82, 1047 1053.
7. Swearingen, B., Barker, F.G., Katznelson, L., Biller, B.M., Grinspoon, S., Klibanski, A., Moayeri, N., Black, P.M. Zervas, N.T. (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism, 83, 3419 3426.
8. Kauppinen-Makelin, R., Sane, T., Reunanen, A., Valimaki, M.J., Niskanen, L., Markkanen, H., Loyttyniemi, E., Ebeling, T., Jaatinen, P., Laine, H., Nuutila, P., Salmela, P., Salmi, J., Stenman, U.H., Viikari, J. Voutilainen, E. (2005) A nationwide survey of mortality in acromegaly. Journal of Clinical Endocrinology and Metabolism, 90, 4081 4086.
9. Rosen, T. Bengtsson, B.A. (1990) Premature mortality due to cardiovascular disease in hypopituitarism. Lancet, 336, 285 288.
10. Bates, A.S., Van't Hoff, W., Jones, P.J. Clayton, R.N. (1996) The effect of hypopituitarism on life expectancy. Journal of Clinical Endocrinology and Metabolism, 81, 1169 1172.
11. Tomlinson, J.W., Holden, N., Hills, R.K., Wheatley, K., Clayton, R.N., Bates, A.S., Sheppard, M.C. Stewart, P.M. (2001) Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet, 357, 425 431.
12. Svensson, J., Tivesten, A. Isgaard, J. (2005) Growth hormone and the cardiovascular function. Minerva Endocrinology, 30, 1 13.
13. Svensson, J., Bengtsson, B.A., Rosen, T., Oden, A. Johannsson, G. (2004) Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. Journal of Clinical Endocrinology and Metabolism, 89, 3306 3312.
14. Barkan, A.L., Clemmons, D.R., Molitch, M.E., Stewart, P.M. Young, W.F. Jr (2000) Growth hormone therapy for hypopituitary adults: time for re-appraisal. Trends in Endocrinology and Metabolism, 11, 238 245.
15. Colao, A., Di Somma, C., Cuocolo, A., Spinelli, L., Acampa, W., Spiezia, S., Rota, F., Savanelli, M.C. Lombardi, G. (2005) Does a gender-related effect of growth hormone (GH) replacement exist on cardiovascular risk factors, cardiac morphology, and performance and atherosclerosis? Results of a two-year open, prospective study in young adult men and women with severe GH deficiency. Journal of Clinical Endocrinology and Metabolism, 90, 5146 5155.
16. Valcavi, R., Gaddi, O., Zini, M., Iavicoli, M., Mellino, U. Portioli, I. (1995) Cardiac performance and mass in adults with hypopituitarism: effects of one year of growth hormone treatment. Journal of Clinical Endocrinology and Metabolism, 80, 659 666.
17. Maison, P. Chanson, P. (2003) Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. Circulation, 108, 2648 2652.
18. Sneppen, S.B., Steensgaard-Hansen, F. Feldt-Rasmussen, U. (2002) Cardiac effects of low-dose growth hormone replacement therapy in growth hormone-deficient adults. An 18-month randomised, placebo-controlled, double-blind study. Hormone Research, 58, 21 29.
19. Climent, V.E., Pico, A., Sogorb, F., Aznar, S., Lip, G.Y. Marin, F. (2006) Growth hormone therapy and the heart. American Journal of Cardiology, 97, 1097 1102.
20. Munagala, V.K., Burnett, J.C. Redfield, M.M. (2004) The natriuretic peptides in cardiovascular medicine. Current Problems in Cardiology, 29, 707 769.
21. Lukowicz, T.V., Fischer, M., Hense, H.W., Doring, A., Stritzke, J., Riegger, G., Schunkert, H. Luchner, A. (2005) BNP as a marker of diastolic dysfunction in the general population: importance of left ventricular hypertrophy. European Journal of Heart Failure, 7, 525 531.
22. Tschope, C., Kasner, M., Westermann, D., Gaub, R., Poller, W.C. Schultheiss, H.P. (2005) The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. European Heart Journal, 26, 2277 2284.
23. Rivera Otero, J.M., Talens-Visconti, R., Salvador, A., Bertomeu, V., Miro, V., Jordan, A., Sogorb, F., Cortes, R., Paya, R., Diago, J.L. Grau, G. (2004) Ventricular hypertrophy increases NT-proBNP in subjects with and without hypertension. International Journal of Cardiology, 96, 265 271.
24. Nishikimi, T., Maeda, N. Matsuoka, H. (2006) The role of natriuretic peptides in cardioprotection. Cardiovascular Research, 69, 318 328.
25. Mueller, T., Gegenhuber, A., Dieplinger, B., Poelz, W. Haltmayer, M. (2004) Long-term stability of endogenous B-type natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP) in frozen plasma samples. Clinical Chemistry and Laboratory Medicine, 42, 942 944.
26. Schou, M., Gustafsson, F., Nielsen, P.H., Madsen, L.H., Kjaer, A. Hildebrandt, P.R. (2007) Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state. European Journal of Heart Failure, 9, 68 74.
27. Kistorp, C., Raymond, I., Pedersen, F., Gustafsson, F., Faber, J. Hildebrandt, P. (2005) N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. Journal of the American Medical Association, 293, 1609 1616.
28. Swedberg, K., Clealand, J., Dargie, H., Drexler, H., Follath, F., Komajda, M., Tavazzi, L. Smiseth, O. (2005) Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). European Heart Journal 26, 1115 1140.
29. Andersen, M., Hansen, T.B., Støving, R.K., Bertelsen, J., Hangaard, J., Hyltoft Petersen, P. Hagen, C. (1996) The pyridostigmine-growth- hormone-releasing-hormone in adults. The reference interval and a comparison with the insulin tolerance test. Endocrinology and Metabolism, 3, 197 206.
30. Landin-Wilhelmsen, K., Wilhelmsen, L., Lappas, G., Rosen, T., Lindstedt, G., Lundberg, P.A. Bengtsson, B.A. (1994) Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clinical Endocrinology, 41, 351 357.
31. Manjunath, G., Sarnak, M.J. Levey, A.S. (2001) Prediction equations to estimate glomerular filtration rate: an update. Current Opinion in Nephrology and Hypertension, 10, 785 792.
32. Harder, B.A., Schaub, M.C., Eppenberger, H.M. Eppenberger-Eberhardt, M. (1996) Influence of fibroblast growth factor (bFGF) and insulin-like growth factor (IGF-I) on cytoskeletal and contractile structures and on atrial natriuretic factor (ANF) expression in adult rat ventricular cardiomyocytes in culture. Journal of Molecular and Cellular Cardiology, 28, 19 31.
33. Hall, C. (2005) NT-ProBNP: the mechanism behind the marker. Journal of Cardiac Failure, 11, S81 S83.
34. O'Shea, M.H. Layish, D.T. (1992) Growth hormone and the kidney: a case presentation and review of the literature. Journal of the American Society of Nephrology, 3, 157 161.
35. Olsen, M.H., Hansen, T.W., Christensen, M.K., Gustafsson, F., Rasmussen, S., Wachtell, K., Borch-Johnsen, K., Ibsen, H., Jorgensen, T. Hildebrandt, P. (2005) N-terminal pro-brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension, 46, 660 666.
36. Kaji, H., Sugimoto, T., Nakaoka, D., Okimura, Y., Kaji, H., Abe, H. Chihara, K. (2001) Bone metabolism and body composition in Japanese patients with active acromegaly. Clinical Endocrinology, 55, 175 181.
37. Bengtsson, B.A., Brummer, R.J. Bosaeus, I. (1990) Growth hormone and body composition. Hormone Research, 33 (Suppl. 4 19 24.
38. Das, S.R., Drazner, M.H., Dries, D.L., Vega, G.L., Stanek, H.G., Abdullah, S.M., Canham, R.M., Chung, A.K., Leonard, D., Wians, F.H. de Lemos, J.A. (2005) Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation, 112, 2163 2168.
39. Oliver, P.M., Fox, J.E., Kim, R., Rockman, H.A., Kim, H.S., Reddick, R.L., Pandey, K.N., Milgram, S.L., Smithies, O. Maeda, N. (1997) Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proceedings of the National Academy of Science of the United States of America, 94, 14730 14735.
40. Schultz, M., Faber, J., Kistorp, C., Jarlov, A., Pedersen, F., Wiinberg, N. Hildebrandt, P. (2004) N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) in different thyroid function states. Clinical Endocrinology, 60, 54 59.
41. Wang, T.J., Larson, M.G., Levy, D., Benjamin, E.J., Leip, E.P., Wilson, P.W. Vasan, R.S. (2004) Impact of obesity on plasma natriuretic peptide levels. Circulation, 109, 594 600.
42. Soszynski, P., Slowinska-Srzednicka, J. Zgliczynski, S. (1991) Plasma concentrations of atrial natriuretic hormone in acromegaly: relationship to hypertension. Acta Endocrinologica (Copenhagen), 125, 268 272.
43. Deray, G., Chanson, P., Maistre, G., Warnet, A., Eurin, J., Barthelemy, C., Masson, F., Martinez, F., Lubetzki, J. Legrand, J.C. (1990) Atrial natriuretic factor in patients with acromegaly. European Journal of Clinical Pharmacology, 38, 409 413.
44. Moller, J., Jorgensen, J.O., Moller, N., Hansen, K.W., Pedersen, E.B. Christiansen, J.S. (1991) Expansion of extracellular volume and suppression of atrial natriuretic peptide after growth hormone administration in normal man. Journal of Clinical Endocrinology and Metabolism, 72, 768 772.
45. McKnight, J.A., McCance, D.R., Hadden, D.R., Kennedy, L., Roberts, G., Sheridan, B. Atkinson, A.B. (1989) Basal and saline-stimulated levels of plasma atrial natriuretic factor in acromegaly. Clinical Endocrinology, 31, 431 438.
46. Ekman, B., Ohman, P.K., Arnqvist, H.J., Lindstrom, T. Nystrom, F.H. (2002) Individualized growth hormone substitution with normalized IGF-I levels does not stimulate the renin-angiotensin-aldosterone system. Clinical Endocrinology, 57, 473 479.
47. Johannsson, G., Sverrisdottir, Y.B., Ellegard, L., Lundberg, P.A. Herlitz, H. (2002) GH increases extracellular volume by stimulating sodium reabsorption in the distal nephron and preventing pressure natriuresis. Journal of Clinical Endocrinology and Metabolism, 87, 1743 1749.